Skip to main content

Advertisement

Log in

Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria

  • Research Article
  • Published:
Pharmacy World & Science Aims and scope Submit manuscript

Abstract

Objective To describe the pattern of anti-diabetic drug prescribing; ascertain the level of glycemic control, adherence with prescribed anti-diabetic medications, and diabetes self management practices among patients with type-2 diabetes in a tertiary care setting in Nigeria. Setting University College Hospital (UCH); a 900 bed teaching hospital with medical residents located in Ibadan, southwestern Nigeria. Method The study consisted of two phases. A cross-sectional review of randomly selected 200 case notes of type 2 diabetic patients that attended the Endocrinology clinic over 3 month; and crosssectional interviews, with a pre-tested Adherence and Self-Management Monitoring Tool (ASMMT), of 200 consecutive patients that presented their drug prescriptions at the satellite pharmacy unit over a 4 week period at a 900-bed teaching hospital located in Ibadan, South-Western Nigeria. Results Oral Hypoglycemic Agents (OHA) were prescribed for 86% (171) of cohorts while insulin and OHA was prescribed in 14% (29). About 70.8% (121) of patients on OHA were on combination therapy. The most frequently prescribed OHA combination was glibenclamide and metformin (95.8%). Glibenclamide was prescribed as twice daily regimen in 69% of cohorts. The most frequently documented side effect was hypoglycemia (60.3%). Only 44% (88) of cohorts had adequate glycemic control; of these, 93% (82) were adjudged adherent with prescribed anti-diabetic drugs. Interviews with the structured ASMMT revealed that 59% of patients were non-adherent with the previous anti-diabetic drugs due to lack of finance (51.7%); side effects (34.5%); perceived inefficacy of prescribed anti-diabetic drugs leading to self-medication with local herbs (13.8%). Only 20% of non-adherent patients claimed disclosure to physicians during consultation. The identified factors for non-disclosure were lack of privacy during consultation (58%); and short consultation time (42%). The knowledge and practice of critical components of diabetes self-management behaviours were generally low among the cohort studied. However, it was significantly higher among patient judged adherent with their prescribed anti-diabetic medications (P < 0.05). Conclusion Majority of patients with type 2 diabetes in an ambulatory tertiary care setting in Nigeria are managed with OHA combinations, mainly glibenclamide and metformin. While the current prescribing strategy achieved glycemic control in about one third of patients, majority are still not meeting the recommended blood glucose targets due to poor adherence with prescribed drug regimen, and poor knowledge and practice of successful self-management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Diabetes Care. 1998;21:1414–31.

    Article  PubMed  CAS  Google Scholar 

  2. World Health Organisation. Diabetes mellitus fact sheet, Number 238. 2002. http://www.who.int/diabetes. Cited 13 Aug 2006.

  3. Haffner SM, Lehto S, Ronnemma T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.

    Article  PubMed  CAS  Google Scholar 

  4. Russell RB, Valiyeva E, Roman SH, Pogach LM, Suh D, Safford MM. Hospitalization, nursing home admission and deaths attributable to diabetes. Diabetes Care. 2005;28:1611–7.

    Article  PubMed  Google Scholar 

  5. Beckman JA, Creager MQ, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.

    Article  PubMed  CAS  Google Scholar 

  6. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J. 2006;332:73–8.

    Article  Google Scholar 

  7. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.

    Article  PubMed  CAS  Google Scholar 

  8. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999;22:S27–31.

    Article  Google Scholar 

  9. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–15.

    Article  Google Scholar 

  10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.

    Article  Google Scholar 

  12. Cohen FJ, Conklin JE, Neslusan CA, Song X. Recent antihyperglyceamic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26(6):1847–51.

    Article  PubMed  Google Scholar 

  13. Turner RC, Cull CA, Fright V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA. 1999;281:2005–12.

    Google Scholar 

  14. Defronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303.

    PubMed  CAS  Google Scholar 

  15. Chuang LM, Tsai ST, Huang BY, Tai TY; Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia- a cross-sectional survey of 24,317 patients with diabetes mellitus in 1998. Diabetes Med. 2002;19:978–85.

    Google Scholar 

  16. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17–20.

    Article  PubMed  Google Scholar 

  17. Wong JS, Rahimah N. Glycemic control of diabetic patients in an urban primary health care setting in Sarawak: the Tanah Putch Health Centre experience. Med J Malaysia. 2004;59(3):411–7.

    PubMed  CAS  Google Scholar 

  18. El-Kebbi IM, Gallina DL, Ziemer DC, et al. Diabetes in urban African-Americans. VI. Utility of fasting or random glucose in identifying poor glycemic control. Diabetes Care. 1998;21(4):501–7.

    Article  PubMed  CAS  Google Scholar 

  19. Ndububa DA, Erhabor GE. Diabetic mortalities in Ilesa, Nigeria: a retrospective study. Cent Afr J Med. 1994;40(10):28–9.

    Google Scholar 

  20. Puepet FH, Agaba EI, Chuhwak EK. Some metabolic abnormalities in type 2 diabetic patients in Jos, north central Nigeria. Niger J Med. 2003;12(4):193–7.

    PubMed  CAS  Google Scholar 

  21. Alebiosu CO. Clinical diabetic neuropathy in a tropical African population. West Afr J Med. 2003;22(2):152–5.

    PubMed  CAS  Google Scholar 

  22. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004;27:2444–9.

    Article  PubMed  Google Scholar 

  23. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–9.

    Article  PubMed  CAS  Google Scholar 

  24. Sullivan PW, Morrato EH, Ghushehyan V, et al. Obesity, inactivity and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the US, 2000–2002. Diabetes Care. 2005;28:1599–603.

    Article  PubMed  Google Scholar 

  25. American Diabetes Association (ADA). Standard of medical care in diabetes. Diabetes Care. 2005;28:S10–20.

    Article  Google Scholar 

  26. Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol. 2004;151:T3–7.

    Article  PubMed  CAS  Google Scholar 

  27. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22(4):313–20.

    Article  PubMed  CAS  Google Scholar 

  28. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary, March 2005. London: BMJ Publishing Group and Royal Pharmaceutical Society of Great Britain; 2005.

  29. American Society of Health-System Pharmacists/American Hospital Formulary Services (ASHP/AHFS). AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2002.

  30. Wan Mohamad WB, Tun Fizi A, Ismail RB, Mafauzy M. Efficacy and safety of Single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. Diabetes Res. 2000;49(2):93–9.

    Article  CAS  Google Scholar 

  31. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycemic control with metformin–glibenclamide combined tablet therapy in type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673–80.

    Article  PubMed  CAS  Google Scholar 

  32. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in amanged care organization: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther. 2002;24(3):460–7.

    Article  PubMed  Google Scholar 

  33. Erasmus RT, Blanco B, Okesina AB, Gqweta Z, Matsha T. Assessment of glycemic control in stable type 2 black south African diabetics attending a peri-urban clinic. Postgrad Med J. 1999;75:603–6.

    PubMed  CAS  Google Scholar 

  34. Kolawole BA, Adegbenro C, Ayoola ZO, Opebiyi B. Diabetes mellitus related treatment goals: awareness and attainment in the Ife-Ijesha zone of south-western Nigeria. Afr J Med Med Sci. 2005;34(4):389–94.

    Google Scholar 

  35. United Nation Development Programme (UNDP). Eye of the needle—Nigeria 2000. New York, USA: Human Development Reports; 2000.

    Google Scholar 

  36. Seltzer HS. Drug induced hypoglycemia. Endocrinol Metab Clin North Am. 1989;18:163–83.

    PubMed  CAS  Google Scholar 

  37. Talabi OA. A questionnaire survey of senior house officers/registrars response to their training at University College Hospital, Ibadan. West Afr J Med. 2003;22(2):108–11.

    Google Scholar 

  38. Ndom RJE, Makanjuola AB. Perceived stress factors among resident doctors in a Nigerian teaching hospital. West Afr J Med. 2004;23(3):78–81.

    Google Scholar 

  39. Ajayi IO, Olumide EA, Oyediran O. Patient satisfaction with the services provided at a general outpatient clinic, Ibadan, Oyo state, Nigeria. Afr J Med Med Sci. 2005;34:133–40.

    PubMed  CAS  Google Scholar 

  40. Glasgow RE, Strycker LA, Hampson SE, Ruggiero L. Personal model beliefs and social-environmental barriers related to diabetes self-management. Diabetes Care. 1997;20:556–61.

    Article  PubMed  CAS  Google Scholar 

  41. Day JL. Diabetic patients education: determinants of success. Diabetes Metab Res Rev. 2000;16(Supl 1):S70–4.

    Article  PubMed  Google Scholar 

  42. Campbell RK. Role of the pharmacists in diabetes management. Am J Health Syst Pharm. 2002;59(9):18–21.

    Google Scholar 

  43. Acheampong JW, Boateng KA, Eghan BA, Story P, Parry EHO, Tomlinson S. The impact of diabetes nurses in the Komfo Anokye Teaching Hospital, Ghana. Diabetes Int. 2000;10:81–3.

    Google Scholar 

  44. Berthoet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective monitoring of compliance is important in management of hypertension. J Clin Hypertens. 2000;2:210–4.

    Google Scholar 

  45. Fodor GJ, Kotrec M, BacsKai K, et al. Is interview a reliable method to verify compliance with antihypertensive therapy? An international central-European study. J Hum Hypertens. 2005;23:1261–6.

    CAS  Google Scholar 

  46. Yusuff KB, Alabi A. Assessing patient adherence to anti-hypertensive drug therapy: can a structured pharmacist-conducted interview separate the wheat from the chaff? Int J Pharm Pract. 2007;15:295–300.

    Article  Google Scholar 

Download references

Acknowledgement

We acknowledge the guidance and support of Prof. Fola Tayo, Department of Clinical Pharmacy & Biopharmacy, Faculty of Pharmacy, University of Lagos, Lagos, Nigeria.

Funding

None

Conflicts of Interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kazeem B. Yusuff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yusuff, K.B., Obe, O. & Joseph, B.Y. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. Pharm World Sci 30, 876–883 (2008). https://doi.org/10.1007/s11096-008-9243-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-008-9243-2

Keywords

Navigation